LS 216

Drug Profile

LS 216

Alternative Names: PDT research programme - Light Sciences; Photodynamic therapy research programme - Light Sciences; Research programme photodynamic therapy - Light Sciences

Latest Information Update: 24 Mar 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer Light Sciences Corporation; Roswell Park Cancer Institute
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Mar 2005 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 24 Feb 2005 No development reported - Phase-I for Cancer in USA (unspecified route)
  • 12 Jun 2002 Phase-I clinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top